{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:24:04Z","timestamp":1761999844799,"version":"build-2065373602"},"reference-count":28,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2017]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Thrombosis after cessation of anticoagulation, also named rebound thrombosis, is a matter of concern and controversy. There are only few published data about occurrence of rebound thrombosis associated with non-vitamin K-antagonist oral anticoagulant drugs (NOACs). We report on a 58-year-old male with paroxysmal atrial fibrillation (AF) with a CHA2DS2VASC score of 4 who developed central pulmonary embolism four days after interruption of rivaroxaban because of parotid surgery. He had received 40 mg enoxaparin\/d. The parotid gland was partially resected within 6 hours without blood loss. Pulmonary embolism and AF occurred on the first postoperative day. He recovered with low-molecular-weight heparin in therapeutic dosages and amiodarone and was discharged with phenprocoumon. The relevance of a rivaroxaban rebound phenomenon, manifesting as arterial embolism, stroke or venous thromboembolism should be clarified. It should be assessed if rebound-phenomena also exist for the NOACs dabigatran, apixaban and edoxaban. Thus, the randomized trials and registries investigating patients with AF or venous thromboembolism should be re-analysed and, based on these data, recommendations should be developed for situations in which NOAC-therapy has to be interrupted or ceased.<\/jats:p>","DOI":"10.5482\/hamo-17-01-0005","type":"journal-article","created":{"date-parts":[[2017,8,30]],"date-time":"2017-08-30T10:37:43Z","timestamp":1504089463000},"page":"302-306","source":"Crossref","is-referenced-by-count":5,"title":["Pulmonary embolism four days after interruption of therapy with rivaroxaban"],"prefix":"10.5482","volume":"37","author":[{"given":"Gabor","family":"G\u00f6nd\u00f6r","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"St\u00f6llberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2017,12,28]]},"reference":[{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-1","DOI":"10.1056\/NEJMoa1009638"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-2","DOI":"10.1056\/NEJMoa1007903"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-3","DOI":"10.1056\/NEJMoa1113572"},{"unstructured":"United States Food and Drug Administration. XARELTO (Rivaroxaban) tablets, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/202439s021lbl.pdf. Initial U.S. Approval: 2011","key":"10.5482\/HAMO-17-01-0005-4"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-5","DOI":"10.1016\/j.jacc.2012.09.057"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-6","DOI":"10.1097\/MCP.0b013e32833c3d3e"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-7","DOI":"10.1111\/j.1538-7836.2005.01166.x"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-8","DOI":"10.1093\/eurheartj\/ehu243"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-9","DOI":"10.1161\/CIRCOUTCOMES.113.000132"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-10","DOI":"10.1016\/j.ijcard.2016.03.148"},{"unstructured":"United States Food and Drug Administration. ELIQUIS (Apixaban) tablets, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202155s000lbl.pdf. Initial U.S. Approval: 2012","key":"10.5482\/HAMO-17-01-0005-11"},{"unstructured":"United States Food and Drug Administration. SAVAYSA (Edoxaban) tablets, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206316lbl.pdf. Initial U.S. Approval: 2015","key":"10.5482\/HAMO-17-01-0005-12"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-13","DOI":"10.1111\/j.1538-7836.2007.02748.x"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-14","DOI":"10.1185\/030079906X89801"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-15","DOI":"10.1136\/bmj.e4469"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-16","DOI":"10.1371\/journal.pone.0156943"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-17","DOI":"10.1046\/j.1365-2141.1996.d01-1499.x"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-18","DOI":"10.1161\/ATVBAHA.112.300053"},{"unstructured":"Caprini JA, Merli GJ, Bhatt DL. Update on Risk Factors for Venous Thromboembolism http:\/\/www.venousdisease.com\/Publications\/Update%20on%20risk%20factors-caprini.pdf. Am J Med 2005","key":"10.5482\/HAMO-17-01-0005-19"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-20","DOI":"10.1017\/S0022215114003405"},{"issue":"3","key":"10.5482\/HAMO-17-01-0005-21","first-page":"31","volume":"69","author":"Chiesa","year":"2015","journal-title":"Otolaryngol Pol"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-22","DOI":"10.1378\/chest.1412S3"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-23","DOI":"10.1016\/j.ijcard.2016.08.089"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-24","DOI":"10.1056\/NEJMoa1501035"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-25","DOI":"10.1182\/blood-2012-06-415943"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-26","DOI":"10.1093\/eurheartj\/eht134"},{"doi-asserted-by":"publisher","key":"10.5482\/HAMO-17-01-0005-27","DOI":"10.1016\/j.amjmed.2016.06.005"},{"issue":"1","key":"10.5482\/HAMO-17-01-0005-28","first-page":"51","volume":"9","author":"Alvarez","year":"2007","journal-title":"Crit Care Resusc"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.5482\/HAMO-17-01-0005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T10:45:20Z","timestamp":1540377920000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.5482\/HAMO-17-01-0005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":28,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2017,12,28]]},"published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.5482\/hamo-17-01-0005","relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"type":"print","value":"0720-9355"},{"type":"electronic","value":"2567-5761"}],"subject":[],"published":{"date-parts":[[2017]]}}}